Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Aldeyra Therapeutics Faces...
Business class action lawsuit

Aldeyra Therapeutics Faces Securities Lawsuits

Analysis based on 80 articles · First reported Apr 24, 2026 · Last updated May 30, 2026

Sentiment
-60
Attention
4
Articles
80
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The multiple class action lawsuits against Aldeyra Therapeutics, stemming from the United States — Food and Drug Administration's Complete Response Letter regarding reproxalap, have severely impacted Aldeyra Therapeutics' stock price. This event highlights the significant risks associated with pharmaceutical drug development and regulatory approvals, potentially leading to investor losses and increased scrutiny on similar biotech companies.

pharmaceuticals legal services
Event Summary

Multiple investor-rights law firms, including Bronstein, Gewirtz & Grossman, LLC, The Schall Law Firm, Rosen Law Firm, and Pomerantz LLP, have filed or are reminding investors about class action lawsuits against Aldeyra Therapeutics. These lawsuits allege that Aldeyra Therapeutics and its officers made false and misleading statements regarding the clinical trials of its drug candidate, reproxalap. The core of the complaint is that the trial results were inconsistent, rendering any positive findings unreliable. This alleged misrepresentation led to investor damages, particularly after the United States — Food and Drug Administration issued a Complete Response Letter on March 17, 2026, stating a 'lack of substantial evidence' for reproxalap's efficacy and highlighting the 'inconsistency of study results.' This news caused Aldeyra Therapeutics' stock price to fall significantly by over 70%. Investors who purchased Aldeyra Therapeutics securities between November 3, 2023, and March 16, 2026, are encouraged to join these lawsuits, with a lead plaintiff deadline of May 29, 2026.

Key Actions
100 DJS Law Group reminded investors of Aldeyra Therapeutics
100 Bronstein, Gewirtz & Grossman, LLC filed class action lawsuit Aldeyra Therapeutics
98 United States — Food and Drug Administration issued Complete Response Letter Aldeyra Therapeutics
91 Rosen Law Firm filed lawsuit Aldeyra Therapeutics
91 Aldeyra Therapeutics stock price fell
85 Kirby McInerney LLP filed lawsuit Aldeyra Therapeutics
80 Faruqi & Faruqi filed class action Aldeyra Therapeutics
80 Aldeyra Therapeutics announced success
76 Rosen Law Firm reminds purchasers
75 Pomerantz LLP filed class action lawsuit Aldeyra Therapeutics
70 The Schall Law Firm reminded investors of lawsuit Aldeyra Therapeutics
Entities Involved
stock
Aldeyra Therapeutics
Aldeyra Therapeutics is the defendant in multiple class action lawsuits alleging securities fraud due to inconsistent clinical trial results for its drug candidate, reproxalap, leading to a significant drop in its stock price after receiving a Complete Response Letter from the United States — Food and Drug Administration.
Importance 100 Sentiment -80
priv
Rosen Law Firm
Rosen Law Firm is a global investor rights law firm that reminds purchasers of Aldeyra Therapeutics securities about the lead plaintiff deadline in the securities class action it first filed.
Importance 90 Sentiment 45
priv
Bronstein, Gewirtz & Grossman, LLC
Bronstein, Gewirtz & Grossman, LLC is an investor-rights law firm that has filed a class action lawsuit against Aldeyra Therapeutics, seeking to recover damages for investors.
Importance 85 Sentiment 40
priv
Pomerantz LLP
Pomerantz LLP announces a class action lawsuit against Aldeyra Therapeutics, advising investors to contact them regarding the case.
Importance 75 Sentiment 38
priv
The Schall Law Firm
The Schall Law Firm is a national shareholder rights litigation firm that reminds investors of a class action lawsuit against Aldeyra Therapeutics for alleged securities law violations.
Importance 70 Sentiment 35
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration issued a Complete Response Letter to Aldeyra Therapeutics, citing a lack of substantial evidence for the efficacy of reproxalap, which triggered the stock price drop and subsequent lawsuits.
Importance 70 Sentiment 0
priv
DJS Law Group
DJS Law Group is one of the law firms reminding investors of the class action lawsuit against Aldeyra Therapeutics and encouraging shareholders to participate.
Importance 70 Sentiment 20
priv
Faruqi & Faruqi
Faruqi & Faruqi is investigating potential claims against Aldeyra Therapeutics and reminding investors of the deadline to seek the role of lead plaintiff in the federal securities class action.
Importance 70 Sentiment 20
priv
Kirby McInerney LLP
Kirby McInerney LLP is the law firm representing investors in the securities class action lawsuit against Aldeyra Therapeutics, seeking lead plaintiff appointments and managing the litigation.
Importance 70 Sentiment 50
per
Peretz Bronstein
Peretz Bronstein is a founding partner of Bronstein, Gewirtz & Grossman, LLC, actively involved in the class action lawsuit against Aldeyra Therapeutics.
Importance 60 Sentiment 30
per
Philip Kim
Philip Kim is an attorney at Rosen Law Firm, providing information and assistance to investors regarding the Aldeyra Therapeutics class action.
Importance 60 Sentiment 30
per
Lawrence Rosen
Lawrence Rosen, a founding partner of Rosen Law Firm, is mentioned as a key figure in the firm's success in securities class actions, which is handling the lawsuit against Aldeyra Therapeutics.
Importance 60 Sentiment 22
oth
Reproxalap
Reproxalap is an investigational drug candidate by Aldeyra Therapeutics for dry eye disease, which failed to receive United States — Food and Drug Administration approval, leading to the company's stock decline and the class action lawsuit.
Importance 60 Sentiment -80
per
Brian Schall
Brian Schall is associated with The Schall Law Firm and encourages investors to contact the firm regarding the Aldeyra Therapeutics class action lawsuit.
Importance 50 Sentiment 25
per
Nathan Miller
Nathan Miller is a Client Relations Manager at Bronstein, Gewirtz & Grossman, LLC, assisting with investor inquiries regarding the Aldeyra Therapeutics class action.
Importance 40 Sentiment 20
+ 6 more entities View on Dashboard
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.